1. Amarsanaa, J.; Batsaikhan, O.; Jargalsaikhan, B.; Kubo, T.; Ghotbi, N.; Kayano, R.; Chimed-Ochir, O. Impact of the COVID-19 pandemic on health emergency and disaster risk management systems: a scoping review of mental health support provided to health care workers. J. Occup. Health 2025, 67, Art. No: uiaf020. DOI: 10.1093/joccuh/uiaf020

2. Shah, R.; Hanna, N.M.; Loo, C.E.; David, M.; Mafra, A.; Fink, H.; McFerran, E.; Garcia, M.; Ghodssighassemabadi, R.; Acharya, S.; Niyibaga, J.; Langselius, O.; Frick, C.; Lasebikan, N.; Vignat, J.; Steinberg, J.; Hughes, S.; Kircher, C.E.; Goldie, C.L.; Egger, S.; Sullivan, R.; Ginsburg, O.; Bray, F.; Caruana, M.; Hui, H.; Ilbawi, A.M.; Canfell, K.; Soerjomataram, I. The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis. Nat. Cancer 2025, 6, 194-204. DOI: 10.1038/s43018-024-00880-4

3. da Silva Chaar Neta, R.; da Silva Batista, C.; Machado Palmerim, É.M.; Costa Dias, H.M.; Costa Nóbrega, K.C.; de Oliveira, C.A.; Visco, D.B. The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson's Disease: a systematic review. Neuroscience 2025, 584, 113-126. DOI: 10.1016/j.neuroscience.2025.08.014

4. Clemente-Suárez, V.J.; Martínez-González, M.B.; Benitez-Agudelo, J.C.; Navarro-Jiménez, E.; Beltran-Velasco, A.I.; Ruisoto, P.; Diaz Arroyo, E.; Laborde-Cárdenas, C.C.; Tornero-Aguilera, J.F. The impact of the COVID-19 pandemic on mental disorders. A critical review. Int. J. Environ. Res. Public Health 2021, 18, Art. No: 10041. DOI: 10.3390/ijerph181910041

5. Pandey, K.; Thurman, M.; Johnson, S.D.; Acharya, A.; Johnston, M.; Klug, E.A.; Olwenyi, O.A.; Rajaiah, R.; Byrareddy, S.N. Mental health issues during and after COVID-19 vaccine era. Brain Res. Bull. 2021, 176, 161-173. DOI: 10.1016/j.brainresbull.2021.08.012

6. O'Connor, H.; DiSalvo, M.; Gersten, M.; Boyden, S.; Uchida, M. Effects of the COVID-19 pandemic on early child development: A systematic review and meta-analysis. J. Dev. Behav. Pediatr. 2025, 46, e227-e239. DOI: 10.1097/dbp.0000000000001352

7. Gianfredi, V.; Scarioni, S.; Marchesi, L.; Ticozzi, E.M.; Addo, M.O.; D'errico, V.; Fratantonio, L.; Liguori, L.; Pellai, A.; Castaldi, S. The impact of the COVID-19 pandemic on academic performance among developmental age students: a systematic review with meta-analysis. Ann. Ig. 2025, 37, 49-73. DOI: 10.7416/ai.2024.2647

8. Littlecott, H.; Krishnaratne, S.; Hummel, J.; Orban, E.; Heinsohn, T.; Noel-Storr, A.H.; Strahwald, B.; Jung-Sievers, C.; Ravens-Sieberer, U.; Rehfuess, E. Unintended consequences of measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review. Cochrane Database Syst. Rev. 2024, 12, Art. No: CD015397. DOI: 10.1002/14651858.CD015397.pub2

9. Lino, M.M.; Mather, S.; Trani, M.; Chen, Y.; Caubel, P.; De Bernardi, B. Challenges and innovations in pharmacovigilance and signal management during the COVID-19 pandemic: an industry perspective. Vaccines (Basel) 2025, 13, Art. No: 481. DOI: 10.3390/vaccines13050481

10. Rudolph, A.; Mitchell, J.; Barrett, J.; Sköld, H.; Taavola, H.; Erlanson, N.; Melgarejo-González, C.; Yue, Q. Y. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Ther. Adv. Drug Saf. 2022, 13, Art. No: 20420986221118972. DOI: 10.1177/20420986221118972

11. Beninger, P.; Caubel, P.; Sharma, L.; Pajovich, G.; Boyd, P. Effects of the COVID-19 pandemic on pharmacovigilance strategy, systems, and processes of large, medium, and small companies: an industry survey. Clin. Ther. 2022, 44, 1225-1236. DOI: 10.1016/j.clinthera.2022.07.007

12. European Medicines Agency. EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines. Available online: https://www.ema.europa.eu/en/news/ema-publishes-safety-monitoring-plan-guidance-risk-management-planning-covid-19-vaccines (accessed on 22 September 2025).

13. Boseley, S.; Oltermann, P. Hopes rise for end of pandemic as Pfizer says vaccine has 90% efficacy. The Guardian. Available online: https://www.theguardian.com/world/2020/nov/09/covid-19-vaccine-candidate-effective-pfizer-biontech (accessed on 4 December 2025).

14. Guarino, B.; Wan, W. First coronavirus vaccine shots given in U.S., starting in New York. The Washington Post. Available online: https://www.washingtonpost.com/nation/2020/12/14/first-covid-vaccines-new-york/ (accessed on 4 December 2025).

15. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency Off. J. Eur. Union 2004, L136, 1–33.

16. European Medicines Agency. COVID-19 vaccines safety update, 8 December 2022. Available online: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf (accessed on 3 December 2025).

17. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2): Collection, management and submission of reports of suspected adverse reactions to medicinal products. Available online: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf (accessed on 3 December 2025).

18. Kiazand, A.; Luther, R.; Marlind Wurtele, J.; Southall, N.; Domalik, D.; Ysander, M. Pandemic vaccines: a formidable challenge for pharmacovigilance. Nat. Rev. Drug Discov. 2023, 22, 1-2. DOI: 10.1038/d41573-022-00178-z

19. Caubel, P. The new post-COVID pharmacovigilance landscape. In Proceedings of the World Drug Safety Congress Europe, Amsterdam, the Netherlands, 4–5 October 2023.

20. Kruk, M. Pharmacovigilance innovations serving the fight against the COVID-19 pandemic. In Proceedings of the World Drug Safety Congress Europe, Amsterdam, the Netherlands, 27-29 September 2022.

21. Kruk, M. Pharmacovigilance of the vaccine against COVID-19. In Proceedings of the XXXIII Nobel Session, Medical University of Warsaw, Warsaw, Poland, 11 December 2023.

22. Carley, S.; Horner, D.; Body, R.; Mackway-Jones, K. Evidence-based medicine and COVID-19: what to believe and when to change. Emerg. Med. J. 2020, 37, 572-575. DOI: 10.1136/emermed-2020-210098

23. Snow, E. K.; Miller, J. L.; Kester, L.; Mendham, N. A.; Heydorn, J. D.; Huang, S. C.; Leu, L. L.; Kohoutek, L. M.; Rosanelli, N. C.; Harves, K. M. Creation and maintenance of a table for assessment of evolving evidence for COVID-19-related treatments. Am. J. Health Syst. Pharm. 2021, 78, 154-157. DOI: 10.1093/ajhp/zxaa334

24. National Institute for Health and Care Excellence. Products: A list of all our products on COVID-19. Available online: https://www.nice.org.uk/guidance/conditions-and-diseases/infections/covid19/products?Status=Published (accessed on 1 December 2025).

25. McMaster Health Forum and the Ottawa Hospital Research Institute. COVID-END: COVID-19 Evidence Network to support Decision-making. Available online: https://www.mcmasterforum.org/networks/covid-end (accessed on 1 December 2025).

26. Agency for Health Technology Assessment and Tariff System. COVID-19: Publication Radar. Available online: https://covid19-radar.aotm.gov.pl/#/ (accessed on 20 June 2023).

27. Agency for Health Technology Assessment and Tariff System. Review of International Guidelines in COVID-19. Available online: https://www.aotm.gov.pl/en/review-of-international-guidelines-in-covid-19/ (accessed on 4 December 2025).

28. Agency for Health Technology Assessment and Tariff System. Recommendations Pharmacotherapy COVID-19. Available online: https://www.aotm.gov.pl/en/covid-19-2/recommendations-in-covid/pharmacotherapy/ (accessed on 4 December 2025).

29. World Health Organization. Global Research on Coronavirus Disease (COVID-19). Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/ (accessed on 4 December 2025).

30. Gautret, P.; Lagier, J. C.; Parola, P.; Hoang, V. T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Tissot Dupont, H.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J. M.; Brouqui, P.; Raoult, D. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 2020, 56, Art. No: 105949. DOI: 10.1016/j.ijantimicag.2020.105949

31. Silva, H.M. Challenges and reflections on pandemic disinformation: the case of hydroxychloroquine and the implications for global public health. Value Health Reg. Issues 2024, 43, Art. No: 101005. DOI: 10.1016/j.vhri.2024.101005

32. Peter Lamy Center on Drug Therapy and Aging at the University of Maryland School of Pharmacy. Optimizing Medication Management During the COVID-19 Pandemic: Implementation Guide for Post-Acute and Long-Term Care. Available online: https://www.pharmacy.umaryland.edu/centers/lamy/optimizing-medication-management-during-covid19-pandemic/ (accessed on 4 December 2025).

33. Shrotri, M.; Swinnen, T.; Kampmann, B.; Parker, E.P.K. An interactive website tracking COVID-19 vaccine development. Lancet Glob. Health 2021, 9, e590-e592. DOI: 10.1016/S2214-109X(21)00043-7

34. Kim, J.H.; Marks, F.; Clemens, J.D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 2021, 27, 205-211. DOI: 10.1038/s41591-021-01230-y

35. Lamprinou, M.; Sachinidis, A.; Stamoula, E.; Vavilis, T.; Papazisis, G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol. Res. 2023, 71, 356-372. DOI: 10.1007/s12026-023-09357-5

36. Fox, S.E.; Akmatbekov, A.; Harbert, J.L.; Li, G.; Quincy Brown, J.; Vander Heide, R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir. Med. 2020, 8, 681-686. DOI: 10.1016/S2213-2600(20)30243-5

37. Lax, S. F.; Skok, K.; Zechner, P.; Kessler, H. H.; Kaufmann, N.; Koelblinger, C.; Vander, K.; Bargfrieder, U.; Trauner, M. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann. Intern. Med. 2020, 173, 350-361. DOI: 10.7326/M20-2566

38. Poor, H.D. Pulmonary thrombosis and thromboembolism in COVID-19. Chest 2021, 160, 1471-1480. DOI: 10.1016/j.chest.2021.06.016

39. Bilotta, C.; Perrone, G.; Adelfio, V.; Spatola, G. F.; Uzzo, M. L.; Argo, A.; Zerbo, S. COVID-19 vaccine-related thrombosis: a aystematic review and exploratory analysis. Front. Immunol. 2021, 12, Art. No: 729251. DOI: 10.3389/fimmu.2021.729251

40. Gollamudi, J.; Sartain, S. E.; Navaei, A. H.; Aneja, S.; Kaur Dhawan, P.; Tran, D.; Joshi, J.; Gidudu, J.; Gollamudi, J.; Chiappini, E.; Varricchio, F.; Law, B.; Munoz, F. M. Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2022, 40, 6431-6444. DOI: 10.1016/j.vaccine.2022.09.001

41. Rahmig, J.; Altarsha, E.; Siepmann, T.; Barlinn, K. Acute ischemic stroke in the context of SARS-CoV-2 vaccination: a systematic review. Neuropsychiatr. Dis. Treat. 2022, 18, 1907-1916. DOI: 10.2147/NDT.S374549

42. Tan, L.J.; Koh, C.P.; Lai, S.K.; Poh, W.C.; Othman, M.S.; Hussin, H. A systemic review and recommendation for an autopsy approach to death followed the COVID 19 vaccination. Forensic Sci. Int. 2022, 340, Art. No: 111469. DOI: 10.1016/j.forsciint.2022.111469.

43. Kontovazainitis, C.G.; Katsaras, G.N.; Gialamprinou, D.; Mitsiakos, G. Covid-19 vaccination and pregnancy: a systematic review of maternal and neonatal outcomes. J. Perinat. Med. 2023, 51, 823-839. DOI: 10.1515/jpm-2022-0463

44. Luxi, N.; Giovanazzi, A.; Capuano, A.; Crisafulli, S.; Cutroneo, P. M.; Fantini, M. P.; Ferrajolo, C.; Moretti, U.; Poluzzi, E.; Raschi, E.; Ravaldi, C.; Reno, C.; Tuccori, M.; Vannacci, A.; Zanoni, G.; Trifirò, G.; Ilmiovaccino COVID19 collaborating group. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf. 2021, 44, 1247-1269. DOI: 10.1007/s40264-021-01131-6

45. Piche-Renaud, P.P.; Morris, S.K.; Top, K.A. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination. Br. J. Clin. Pharmacol. 2023, 89, 967-981. DOI: 10.1111/bcp.15625

46. Sun, H.; Bu, F.; Li, L.; Zhang, X.; Yan, J.; Huang, T. COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews. Front. Public Health 2022, 10, Art. No: 1072137. DOI: 10.3389/fpubh.2022.1072137

47. Baba, C.; Ozcelik, S.; Kaya, E.; Samedzada, U.; Ozdogar, A. T.; Cevik, S.; Dogan, Y.; Ozakbas, S. Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies. Mult. Scler. Relat. Disord. 2022, 68, Art. No: 104119. DOI: 10.1016/j.msard.2022.104119

48. Wallach, A.I.; Schiebel, M.; Picone, M.A. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies. Mult. Scler. Relat. Disord. 2022, 63, Art. No: 103856. DOI: 10.1016/j.msard.2022.103856

49. Cook, C. E.; Patel, N. J.; Fu, X.; Wang, X.; Kawano, Y.; Vanni, K. M. M.; Qian, G.; Banasiak, E.; Kowalski, E.; Choi, H. K.; Zhang, Y.; Sparks, J. A.; Wallace, Z. S. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines against COVID-19 infection among patients with systemic autoimmune rheumatic diseases on immunomodulatory medications. J. Rheumatol. 2023, 50, 697-703. DOI: 10.3899/jrheum.220870

50. La Costa, R. COVID-19 vaccine effectiveness in oncology patients. J. Adv. Pract. Oncol. 2022, 13, 441-447. DOI: 10.6004/jadpro.2022.13.4.6

51. Mekkawi, R.; Elkattan, B.A.; Shablak, A.; Bakr, M.; Yassin, M.A.; Omar, N.E. COVID-19 vaccination in cancer patients: A Review Article. Cancer Control 2022, 29, Art. No: 10732748221106266. DOI: 10.1177/10732748221106266

52. Britton, A.; Embi, P. J.; Levy, M. E.; Gaglani, M.; DeSilva, M. B.; Dixon, B. E.; Dascomb, K.; Patel, P.; Schrader, K. E.; Klein, N. P.; Ong, T. C.; Natarajan, K.; Hartmann, E.; Kharbanda, A. B.; Irving, S. A.; Dickerson, M.; Dunne, M. M.; Raiyani, C.; Grannis, S. J.; Stenehjem, E.; Zerbo, O.; Rao, S.; Han, J.; Sloan-Aagard, C.; Griggs, E.P.; Weber, Z.A.; Murthy, K.; Fadel,W.F.; Grisel, N.; McEvoy, C.; Lewis, N.; Barron, M.A.; Nanez, J.; Reese, S.E.; Mamawala, M.; Valvi, N.R.; Arndorfer, J.; Goddard, K.; Yang, D.H.; Fireman, B.; Ball, S.W.; Link-Gelles, R.; Naleway, A.L.; Tenforde, M.W. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb. Mortal. Wkly. Rep. 2021, 71, 1335-1342. DOI: 10.15585/mmwr.mm7142a4

53. Jatoi, H. N.; Abbas, S.; Abbasi, M. S.; Tauni, M. A.; Ghazanfar, S.; Zafar Malick, M. D.; Umar, M. F.; Tahir, M. J.; Asghar, M. S.; Ahmed, A. BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective. Ann. Med. Surg. (Lond). 2022, 78, Art. No: 103796. DOI: 10.1016/j.amsu.2022.103796

54. Kreuzberger, N.; Hirsch, C.; Andreas, M.; Böhm, L.; Bröckelmann, P. J.; Di Cristanziano, V.; Golinski, M.; Hausinger, R. I.; Mellinghoff, S.; Lange, B.; Lischetzki, T.; Kappler, V.; Mikolajewska, A.; Monsef, I.; Park, Y. S.; Piechotta, V.; Schmaderer, C.; Stegemann, M.; Vanshylla, K.; Weber, F.; Weibel, S.; Stephani, C.; Skoetz, N. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst. Rev. 2022, 8, Art. No: CD015021. DOI: 10.1002/14651858.CD015021

55. Marinho, A. Vaccination in children with immune-mediated disorders. J. Pediatr. (Rio J.) 2023, 99, Suppl 1(Suppl 1):S62-S69. DOI: 10.1016/j.jped.2022.11.008

56. American Academy of Neurology. COVID-19 Resource Center. Available online: https://www.aan.com/tools-resources/covid-19-resources (accessed on 4 December 2025).

57. Quinn, G. A.; Connolly, R.; ÓhAiseadha, C.; Hynds, P.; Bagus, P.; Brown, R. B.; Cáceres, C. F.; Craig, C.; Connolly, M.; Domingo, J. L.; Fenton, N.; Frijters, P.; Hatfill, S.; Heymans, R.; Joffe, A. R.; Jones, R.; Lauc, G.; Lawrie, T.; Malone, R. W.; Mordue, A.; Mushet, G.; O'Connor, A.; Orient, J.; Peña-Ramos, J.A.; Risch, H.A.; Rose, J.; Sánchez-Bayón, A.; Savaris R.F.; Schippers M.C.; Simandan, D.; Sikora, K.; Soon, W.; Shir-Raz, Y.; Spandidos, D.A.; Spira, B.; Tsatsakis, A.M.; Walach, H. What lessons can be learned from the management of the COVID-19 pandemic? Int. J. Public Health 2025, 70, Art. No: 1607727. DOI: 10.3389/ijph.2025.1607727

58. Ferreira-da-Silva, R.; Lobo, M.F.; Pereira, A.M.; Morato, M.; Polonia, J.J.; Ribeiro-Vaz, I. Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance. Front. Med. (Lausanne). 2025, 12, Art. No: 1501921. DOI: 10.3389/fmed.2025.1501921

59. National Library of Medicine. PubMed. Search strategy: ((COVID-19[Title/Abstract]) AND (vaccine[Title/Abstract] OR vaccination[Title/Abstract])) AND (hesitancy[Title/Abstract]). Available online: https://pubmed.ncbi.nlm.nih.gov/advanced/ (accessed on 18 February 2023).

60. Capurro, G.; Tustin, J.; Jardine, C.G.; Driedger, S.M. When good messages go wrong: Perspectives on COVID-19 vaccines and vaccine communication from generally vaccine accepting individuals in Canada. Hum. Vaccin. Immunother. 2022, 18, Art. No: 2145822. DOI: 10.1080/21645515.2022.2145822

61. Lodyga, M.; Maciejewska, K.; Rydzewska, G. A prospective questionnaire-based study to evaluate factors affecting the decision to receive COVID-19 vaccination in 267 patients with inflammatory bowel disease in Poland. Med. Sci. Monit. 2022, 28, Art. No: e938665. DOI: 10.12659/MSM.938665

62. Conger, K. Stanford Medicine. How misinformation, medical mistrust fuel vaccine hesitancy. Available online: https://med.stanford.edu/news/all-news/2021/09/infodemic-covid-19.html (accessed on 4 December 2025).

63. InterAcademy Partnership. Countering COVID-19 Vaccine Hesitancy: Report of an IAP Webinar With Recommendations for Action. Available online: https://www.interacademies.org/sites/default/files/2022-04/Countering%20COVID-19%20Vaccine%20Hesitancy%20final.pdf (accessed on 4 December 2025).

64. InterAcademy Partnership. World Immunization Week: Check Our New Infographic on COVID-19 Vaccines and Fight Vaccine Hesitancy With IAP. Available online: https://www.interacademies.org/news/world-immunization-week-infographic-covid-19-vaccines (accessed on 4 December 2025).

65. van den Ouweland, F.; Charpentier, N.; Türeci, Ö.; Rizzi, R.; Mensa, F. J.; Lindemann, C.; Pather, S. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. Hum. Vaccin. Immunother. 2024, 20, Art. No: 2315659. DOI: 10.1080/21645515.2024.2315659

66. Ip, S.; North, T. L.; Torabi, F.; Li, Y.; Abbasizanjani, H.; Akbari, A.; Horne, E.; Denholm, R.; Keene, S.; Denaxas, S.; Banerjee, A.; Khunti, K.; Sudlow, C.; Whiteley, W. N.; Sterne, J. A. C.; Wood, A. M.; Walker, V.; CVD-COVID-UK/COVID-IMPACT Consortium; Longitudinal Health and Wellbeing COVID-19 National Core Study. Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England. Nat. Commun. 2024, 15, Art. No: 6085. DOI: 10.1038/s41467-024-49634-x

67. Thurin, N.H. Risk assessment of 32 adverse events of special interest following COVID-19 vaccination in the French population. In Abstracts of the 24th ISoP Annual Meeting: Pharmacovigilance: Back to the Future; Cairo, Egypt, 24–27 October 2025; Drug Saf. 2025, 48, 1433–1660.

68. European Medicines Agency. COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines. Available online: https://www.ema.europa.eu/en/news/covid-19-ema-sets-infrastructure-real-world-monitoring-treatments-vaccines (accessed on 3 December 2025).

69. Shivji, R.; Conocchia, R.; Korakianiti, E.; Jekerle, V. Considerations for the chemistry, manufacturing and controls (CMC) - quality package for COVID-19 vaccines: interim lessons learnt by the European Medicines Agency (EMA). Vaccine 2022, 40, 5539-5541. DOI: 10.1016/j.vaccine.2022.06.058

70. US Food & Drug Administration. COVID-19 Vaccine Safety Surveillance. Available online: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-vaccine-safety-surveillance (accessed on 3 December 2025).

71. Oosterhuis, I.; Scholl, J.; van Puijenbroek, E.; Kant, A.; van Hunsel, F. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug Saf. 2023, 46, 65-75. DOI: 10.1007/s40264-022-01253-5

72. Crommelynck, S.; Thill, P. Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France. Infect. Dis. Now 2022, 52, S16-S18. DOI: 10.1016/j.idnow.2022.09.018

73. Italian Medicines Agency. New National Pharmacovigilance Network (RNF) launched. Available online: https://www.aifa.gov.it/en/-/al-via-la-nuova-rnf (accessed on 3 December 2025).

74. Torjesen, I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ (Clinical research ed.) 2021, 372, Art. No: n149. DOI: 10.1136/bmj.n149

75. Republic of Poland, The Ombudsman for Patients' Rights. The Protective Vaccination Compensation Fund has expanded its scope. Available online: https://www.gov.pl/web/rpp/fundusz-kompensacyjny-szczepien-ochronnych-rozszerzyl-swoj-zakres (accessed on 4 December 2025).

76. Fundusz Kompensacyjny – działanie, zmiany w 2023 r. [Compensation Fund – operation, changes in 2023]. Available online: https://www.infor.pl/prawo/prawa-konsumenta/prawa-pacjenta/5625219,fundusz-kompensacyjny-odszkodowanie-nop-zmiany-2023.html (accessed on 4 December 2025).

77. Ministry of Health, Israel. תופעות אשר דווחו על ידי הציבור בסמיכות לקבלת חיסון נגד נגיף הקורונה: דוח מסכם לתקופה 09/12/2021-31/05/2022 [Adverse events reported by the public in proximity to COVID-19 vaccination: Summary report for the period 9 December 2021–31 May 2022]. Ministry of Health: Jerusalem, Israel, 2022.

78. Ministry of Health, Israel. תופעות שהופיעו בסמיכות לקבלת חיסון נגד קורונה [Adverse events occurring in temporal proximity to COVID-19 vaccination]. Ministry of Health: Jerusalem, Israel, 2021.

79. Israel Ministry of Health. Proceedings of the Committee on COVID-19 Vaccine Effectiveness and Safety. Available online: https://www.gov.il/en/pages/vaccine-efficacy-safety-follow-up-committee (accessed on 20 December 2025).